Puma Biotechnology Q2 Earnings Surprise: Revenue Down 9.3%, EPS Down 54%

Puma Biotechnology's Q2 results exceeded expectations, with revenues of $52m and EPS of $0.12, up 25% from estimates. The analyst has updated their earnings model, with forecasts for 2025 showing a 9.3% decline in revenue and a 54% drop in EPS. The consensus price target fell 36% to $3.00.

Puma Biotechnology (PBYI) reported robust Q2 2025 results, with revenues of $52 million and EPS of $0.12, surpassing analysts' expectations. The company's earnings model has been updated, projecting a 9.3% decline in revenue and a 54% drop in EPS for 2025, while the consensus price target fell 36% to $3.00.

The company's Q2 2025 revenue surged 11.4% to $52.4 million, driven by NERLYNX's $49.2 million net sales and 28% lower SG&A costs [1]. Non-GAAP EPS of $0.15 beat estimates, with $5.9 million net income versus a $4.5 million loss in Q2 2024, showcasing a profitability turnaround [1]. Puma's gross-to-net adjustment of 21.5%–22.0% for 2025 signals strong pricing power, while strategic EMEA partnerships and 21.5-22% pricing power reinforce NERLYNX's dominance [1].

The company's strategic initiatives, such as optimizing the dosing regimen for NERLYNX and expanding globally through partnerships, have contributed to its strong performance [2]. However, analysts have revised their earnings models due to concerns about the competitive landscape and regulatory hurdles [1].

Puma Biotechnology's Q2 results and pipeline updates paint a picture of a company that's profitable today and innovating for tomorrow. With NERLYNX providing stable cash flow, alisertib offering high-margin growth, and a management team that prioritizes efficiency, PBYI is a rare biotech play that balances near-term visibility with long-term potential. For those willing to ride the wave of precision oncology, Puma is a strategic buy—especially at current valuations that still understate its pipeline's upside [1].

References:
[1] https://www.ainvest.com/news/puma-biotechnology-q2-earnings-outperformance-nerlynx-momentum-signal-strategic-buy-opportunity-2508/
[2] https://www.investing.com/news/company-news/puma-biotechnology-q2-2025-slides-nerlynx-revenue-grows-14-quarteroverquarter-93CH-4179963